Catalogue Number: 10415-IBL
|Manufacturer:||IBL - (Immuno-Biologicals Laboratories Co Ltd)|
|Physical state:||Lyophilized product from 1.0 mL of PBS containing 1 % BSA and 0.05 % NaN3|
|Type:||Monoclonal Primary Antibody - Unconjugated|
|Shipping Condition:||Blue Ice|
|Unit(s):||100 ug, 10 ug|
|Immunogen:||Synthetic peptide of the N-terminal part of human CD20 (CMQSGPKPLFRRMSS)|
Description: Rituximab used for treatment of lymphoma is an antibody drug of which target is pan-B cell marker, CD20. It has been reported that the C-terminal region of CD20 undertakes a critical role in a binding to rituximab and the association between C-terminal mutations and rituximab-resistance has been investigated. This antibody was developed as a new monoclonal antibody that recognizes the N-terminal region of CD20 molecule to detect comprehensive CD20 regardless of C-terminal mutations. It is expected to be useful for the detailed examination of CD20 molecules by adding this antibody to reserch of CD20.